Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05020860
Title A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome in Patients With Early Stage Breast Cancer (RESPONSE)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Baylor Breast Care Center

estrogen-receptor positive breast cancer

Her2-receptor positive breast cancer

triple-receptor negative breast cancer


Cyclophosphamide + Doxorubicin + Paclitaxel

Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel

Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.